Skip to content

Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5

Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05970094
Acronym
REMA-CKD
Enrollment
20
Registered
2023-08-01
Start date
2023-03-06
Completion date
2023-11-20
Last updated
2023-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD, Kidney Diseases, Metabolic Acidosis, Pre-dialysis, Renal Insufficiency

Keywords

Potential renal acid load, PRAL, Study design, Diet, Humans, Elderly, Bicarbonate/blood, Muscle strength, Hand strength, Chair stand test, Calorimetry, indirect, Bone mineralization, Carbon dioxide/blood, Phosphor/urine, Potassium/urine, Urea/blood, Urea/urine

Brief summary

The goal of this clinical trial is to learn about and test the effect of an acid/base diet, in chronic kidney patients with CKD stage 4 and 5 in an interventional study with a historical control. The hypothesize is, that an acid/base diet will reduce the degree of acidosis and the need for oral bicarbonate supplements.

Detailed description

Observational studies indicate that diets with a low potential renal acid load (PRAL) is associated with a lower serum-bicarbonate value. The aim is to investigate this association with an interventional studydesign. Participants will be asked to follow a restricted diet with a low PRAL during a 6 week trial divided in three periodes: two week free living control, two week intervention and a two week free living follow-up. The PRAL calculation tool will be used to create a diet low in acid, based on this the patients will receive individual diet plans. The diet will comply with national treshold guidelines for potassium and protein, this is due to the high risk of hyperkalemia in patients with chronic kidney disease. The patients will be asked to document their food and drink intake by taking pictures of their plates and cups before and after a meal, over a 24 hour period.

Interventions

Two weeks on a low PRAL diet compared to 2 week free living

Sponsors

Nordsjaellands Hospital
CollaboratorOTHER
University of Copenhagen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Crossover design: 1 arm consisting of three consecutive periods of two weeks (control, intervention and follow up).

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic acidosis (plasma-bicarbonat under 22 mmol/l at multiple measures within the last 12 months). * Diagnosed with non-dialysis needed chronic kidney disease in stage 4 and 5 (eGFR below 30 ml/min/1,73 m2) * Of legal age and over 18 of years * Understand danish and understand the written material * Able to cooperate about the diet * Able to take pictures with their phone or willing to learn

Exclusion criteria

* Vegan and vegetarian with very low intake of animal protein (below 25 g/day) * Pregnant or breast feeding * Patients with short bowel syndrome, brickre's bladder, pancreatitis or any other known malabsorption problem * Potassium above 5 mmol/l * Ongoing infection

Design outcomes

Primary

MeasureTime frameDescription
Plasma-total CO26 weeksmmol/l

Secondary

MeasureTime frameDescription
Urine-potassium6 weeksmmol/d
Urine-pH6 weeksUnits
Urine NH4+ excretion6 weeksmmol/day
Urine net acid excretion6 weeksmeqv/day
Urine bicarbonate6 weeksmmol/l
Plasma-alkaline phosphatase6 weeksU/l
Plasma-sodium ion6 weeksmmol/l
Plasma-creatinine6 weeksumol/l
Plasma-parathyroid hormone6 weekspmol/l
Plasma-carbamide6 weeksmmol/l
Plasma-albumin6 weeksg/l
Urine-phosphorous6 weeksmmol/d
Urine-sodium6 weeksmmol/d
Urine-carbamide6 weeksmmol/d
Urine-albumin6 weeksmg/d
Urine-magnesium6 weeksmmol/d
Urine-creatinine6 weeksmmol/d
Uirne-calcium6 weeksmmol/d
Total acid excretion in urine6 weeksmeqv/day

Other

MeasureTime frameDescription
Plasma-magnesium6 weeksmmol/l
Plasma-inorganic phosphorous6 weeksmmol/l
Plasma-Potassium6 weeksmmol/l
Plasma-calcium6 weeksmmol/l

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026